{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T04:11:22Z","timestamp":1788495082650,"version":"build-2803163510"},"reference-count":59,"publisher":"Oxford University Press (OUP)","issue":"9","license":[{"start":{"date-parts":[[2019,7,11]],"date-time":"2019-07-11T00:00:00Z","timestamp":1562803200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"},{"start":{"date-parts":[[2019,7,11]],"date-time":"2019-07-11T00:00:00Z","timestamp":1562803200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["jsm.jsexmed.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2019,9,1]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n               <jats:sec>\n                  <jats:title>Introduction<\/jats:title>\n                  <jats:p>Sexual function can be impaired by all prostate cancer treatment modalities, but studies specifically addressing the impact of stereotactic body radiotherapy (SBRT) on sexual function are scarce.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Aim<\/jats:title>\n                  <jats:p>To systematically evaluate sexual outcomes in patients treated by SBRT for prostate cancer and determine clinical factors associated with erectile dysfunction (ED).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>A systematic review of the available literature was performed on PubMed\/Medline, Scopus, and Cochrane Library databases in June 2017 according to the Preferred Reporting Items for Systematic Review and Meta-analysis statement. Only articles providing data on baseline and post-treatment sexual function after SBRT (\u22655 Gy\/fraction) were included in this analysis (n = 12).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Main Outcome Measure<\/jats:title>\n                  <jats:p>Sexual function deteriorates after SBRT of the prostate.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>Deterioration of sexual health was found, with Expanded Prostate Cancer Index Composite\u201326 sexual domain scores showing a median decrease of 9.2 at 12 months and a median decrease of the Sexual Health Inventory for Men subdomain score by 2.7 at 12 months (from baseline median value of 56.3 and 16, respectively). At 60 months, ED was reported by 26\u201355% of previously sexually functioning patients in 5 of the 12 studies.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Clinical Implications<\/jats:title>\n                  <jats:p>ED affects \u226455% of previously sexually functioning patients at 5 years, as reported for other non-surgical treatment modalities.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Strengths &amp; Limitations<\/jats:title>\n                  <jats:p>This study enforced strict inclusion criteria of selected studies and exclusion of patients receiving concurrent androgen deprivation therapy. However, inconsistencies in the choice of assessment tool and definition of ED hamper a robust meta-analysis of pooled data.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusion<\/jats:title>\n                  <jats:p>Sexual function decline after SBRT for prostate cancer appears to be similar to other modalities and should be specifically addressed in future studies.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1016\/j.jsxm.2019.05.019","type":"journal-article","created":{"date-parts":[[2019,7,11]],"date-time":"2019-07-11T22:09:15Z","timestamp":1562882955000},"page":"1409-1420","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":32,"title":["Sexual Function in Patients Treated With Stereotactic Radiotherapy For Prostate Cancer: A Systematic Review of the Current Evidence"],"prefix":"10.1093","volume":"16","author":[{"given":"Mauro","family":"Loi","sequence":"first","affiliation":[{"name":"Department of Radiation Oncology , Florence , Italy"},{"name":"University of Florence , Florence , Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruud C.","family":"Wortel","sequence":"additional","affiliation":[{"name":"Department of Urology , Utrecht , the Netherlands"},{"name":"University Medical Center Utrecht , Utrecht , the Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giulio","family":"Francolini","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology , Florence , Italy"},{"name":"University of Florence , Florence , Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luca","family":"Incrocci","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology , Rotterdam , the Netherlands"},{"name":"Erasmus MC Cancer Institute , Rotterdam , the Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2019,7,11]]},"reference":[{"key":"2023010721202101500_bib1","first-page":"JCO1801097","article-title":"Hypofractionated radiation therapy for localized prostate cancer: An ASTRO, ASCO, and AUA evidence-based guideline","author":"Morgan","year":"2018  11","journal-title":"J Clin Oncol"},{"key":"2023010721202101500_bib2","doi-asserted-by":"crossref","first-page":"1095","DOI":"10.1016\/S0360-3016(98)00438-6","article-title":"Fractionation and protraction for radiotherapy of prostate carcinoma","volume":"43","author":"Brenner","year":"1999","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"2023010721202101500_bib3","doi-asserted-by":"crossref","first-page":"4161","DOI":"10.1118\/1.2969065","article-title":"Some implications of linear-quadratic-linear radiation dose-response with regard to hypofractionation","volume":"35","author":"Astrahan","year":"2008","journal-title":"Med Phys"},{"key":"2023010721202101500_bib4","doi-asserted-by":"crossref","first-page":"781340","DOI":"10.1155\/2014\/781340","article-title":"Hypofractionation in prostate cancer: Radiobiological basis and clinical appliance","volume":"2014","author":"Mangoni","year":"2014","journal-title":"Biomed Res Int"},{"key":"2023010721202101500_bib5","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/j.urolonc.2016.06.002","article-title":"What is the best way to radiate the prostate in 2016?","volume":"35","author":"Moon","year":"2017","journal-title":"Urol Oncol"},{"key":"2023010721202101500_bib6","doi-asserted-by":"crossref","first-page":"1260","DOI":"10.1016\/j.jsxm.2017.08.005","article-title":"Reporting erectile function outcomes after radiation therapy for prostate cancer: Challenges in data interpretation","volume":"14","author":"Wortel","year":"2017","journal-title":"J Sex Med"},{"key":"2023010721202101500_bib7","doi-asserted-by":"crossref","first-page":"i4919","DOI":"10.1136\/bmj.i4919","article-title":"ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions","volume":"355","author":"Sterne","year":"2016  12","journal-title":"BMJ"},{"key":"2023010721202101500_bib8","doi-asserted-by":"crossref","first-page":"260","DOI":"10.3857\/roj.2015.01571","article-title":"Hypofractionated stereotactic body radiotherapy in low- and intermediate-risk prostate carcinoma","volume":"34","author":"Kim","year":"2016","journal-title":"Radiat Oncol J"},{"key":"2023010721202101500_bib9","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1016\/j.prro.2015.11.002","article-title":"SBRT and HDR brachytherapy produce lower PSA nadirs and different PSA decay patterns than conventionally fractionated IMRT in patients with low- or intermediate-risk prostate cancer","volume":"6","author":"Kishan","year":"2016","journal-title":"Pract Radiat Oncol"},{"key":"2023010721202101500_bib10","doi-asserted-by":"crossref","first-page":"289","DOI":"10.5173\/ceju.2015.582","article-title":"CyberKnife-based prostate cancer patient radioablation\u2014Early results of irradiation in 200 patients","volume":"68","author":"Miszczyk","year":"2015","journal-title":"Cent European J Urol"},{"key":"2023010721202101500_bib11","doi-asserted-by":"crossref","first-page":"684","DOI":"10.5301\/tj.5000355","article-title":"Stereotactic ablative radiotherapy with CyberKnife in the treatment of locally advanced prostate cancer: preliminary results","volume":"101","author":"Fan","year":"2015","journal-title":"Tumori"},{"key":"2023010721202101500_bib12","doi-asserted-by":"crossref","first-page":"710","DOI":"10.3346\/jkms.2015.30.6.710","article-title":"Stereotactic body radiation therapy for low- to intermediate-risk prostate adenocarcinoma","volume":"30","author":"Jeong","year":"2015","journal-title":"J Korean Med Sci"},{"key":"2023010721202101500_bib13","doi-asserted-by":"crossref","first-page":"188","DOI":"10.3109\/07357907.2015.1019679","article-title":"Cyberknife treatment for low and intermediate risk prostate cancer","volume":"33","author":"Detti","year":"2015","journal-title":"Cancer Invest"},{"issue":"28","key":"2023010721202101500_bib14","doi-asserted-by":"crossref","first-page":"e290","DOI":"10.1097\/MD.0000000000000290","article-title":"Stereotactic body radiation therapy for prostate cancer patients with old age or medical comorbidity: a 5-year follow-up of an investigational study","volume":"93","author":"Lee","year":"2014","journal-title":"Medicine (Baltimore)"},{"key":"2023010721202101500_bib15","doi-asserted-by":"crossref","first-page":"336","DOI":"10.3389\/fonc.2014.00336","article-title":"A phase II study of stereotactic body radiation therapy for low-intermediate-high-risk prostate cancer using helical tomotherapy: Dose-volumetric parameters predicting early toxicity","volume":"4","author":"Macias","year":"2014","journal-title":"Front Oncol"},{"key":"2023010721202101500_bib16","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1016\/j.clon.2014.08.007","article-title":"Prostate stereotactic body radiotherapy\u2014First UK experience","volume":"26","author":"Tree","year":"2014","journal-title":"Clin Oncol (R Coll Radiol)"},{"key":"2023010721202101500_bib17","doi-asserted-by":"crossref","first-page":"172","DOI":"10.4111\/kju.2014.55.3.172","article-title":"Clinical outcomes of CyberKnife radiotherapy in prostate cancer patients: Short-term, single-center experience","volume":"55","author":"Koh","year":"2014","journal-title":"Korean J Urol"},{"key":"2023010721202101500_bib18","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1186\/1748-717X-9-42","article-title":"Hypofractionated SBRT versus conventionally fractionated EBRT for prostate cancer: Comparison of PSA slope and nadir","volume":"9","author":"Anwar","year":"2014","journal-title":"Radiat Oncol"},{"key":"2023010721202101500_bib19","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1186\/1471-2490-13-49","article-title":"A single-center study of 100 consecutive patients with localized prostate cancer treated with stereotactic body radiotherapy","volume":"13","author":"Bolzicco","year":"2013","journal-title":"BMC Urol"},{"key":"2023010721202101500_bib20","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1186\/1748-717X-6-3","article-title":"Stereotactic body radiotherapy for low-risk prostate cancer: Five-year outcomes","volume":"6","author":"Freeman","year":"2011","journal-title":"Radiat Oncol"},{"key":"2023010721202101500_bib21","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1089\/end.2009.0438","article-title":"CyberKnife stereotactic radiotherapy as monotherapy for low- to intermediate-stage prostate cancer: Early experience, feasibility, and tolerance","volume":"24","author":"Aluwini","year":"2010","journal-title":"J Endourol"},{"key":"2023010721202101500_bib22","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1177\/030089161109700109","article-title":"Image-guided stereotactic body radiation therapy for localized prostate cancer","volume":"97","author":"Kang","year":"2011","journal-title":"Tumori"},{"key":"2023010721202101500_bib23","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1007\/s13566-015-0237-0","article-title":"Propensity score matched comparison of SBRT versus IMRT for the treatment of localized prostate cancer","volume":"5","author":"Oliai","year":"2016","journal-title":"J Radiat Oncol"},{"key":"2023010721202101500_bib24","doi-asserted-by":"crossref","first-page":"e173","DOI":"10.1016\/j.clon.2016.06.013","article-title":"High-quality linac-based stereotactic body radiation therapy with flattening filter free beams and volumetric modulated arc therapy for low-intermediate risk prostate cancer. A mono-institutional experience with 90 patients","volume":"28","author":"D'Agostino","year":"2016","journal-title":"Clin Oncol"},{"key":"2023010721202101500_bib25","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/j.radonc.2015.07.016","article-title":"Patient-reported quality of life after stereotactic body radiotherapy (SBRT), intensity modulated radiotherapy (IMRT), and brachytherapy","volume":"116","author":"Evans","year":"2015","journal-title":"Radiother Oncol"},{"key":"2023010721202101500_bib26","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1177\/1533034614566994","article-title":"High-dose robotic stereotactic body radiotherapy in the treatment of patients with prostate cancer: Preliminary results in 26 patients","volume":"15","author":"Pontoriero","year":"2016","journal-title":"Technol Cancer Res Treat"},{"key":"2023010721202101500_bib27","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1016\/j.radonc.2016.10.013","article-title":"Patient-reported quality of life after stereotactic body radiation therapy versus moderate hypofractionation for clinically localized prostate cancer","volume":"121","author":"Johnson","year":"2016","journal-title":"Radiother Oncol"},{"key":"2023010721202101500_bib28","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1016\/j.radonc.2014.10.013","article-title":"A comparative study of quality of life in patients with localized prostate cancer treated at a single institution: Stereotactic ablative radiotherapy or external beam + high dose rate brachytherapy boost","volume":"113","author":"Helou","year":"2014","journal-title":"Radiother Oncol"},{"key":"2023010721202101500_bib29","doi-asserted-by":"crossref","first-page":"312","DOI":"10.3389\/fonc.2014.00312","article-title":"SBRT for the primary treatment of localized prostate cancer: The effect of Gleason score, dose and heterogeneity of intermediate risk on outcome utilizing 2.2014 NCCN Risk Stratification Guidelines","volume":"4","author":"Bernetich","year":"2014","journal-title":"Front Oncol"},{"key":"2023010721202101500_bib30","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1186\/1748-717X-8-256","article-title":"Potency preservation following stereotactic body radiation therapy for prostate cancer","volume":"8","author":"Obayomi-Davies","year":"2013","journal-title":"Radiat Oncol"},{"key":"2023010721202101500_bib31","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1186\/1748-717X-8-58","article-title":"Stereotactic body radiation therapy (SBRT) for clinically localized prostate cancer: The Georgetown University experience","volume":"8","author":"Chen","year":"2013","journal-title":"Radiat Oncol"},{"key":"2023010721202101500_bib32","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1186\/s13014-014-0241-3","article-title":"Stereotactic body radiation therapy (SBRT) for prostate cancer in men with large prostates (\u226550 cm(3))","volume":"9","author":"Janowski","year":"2014","journal-title":"Radiat Oncol"},{"key":"2023010721202101500_bib33","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1186\/1748-717X-8-30","article-title":"Hypofractionated stereotactic body radiation therapy as monotherapy for intermediate-risk prostate cancer","volume":"8","author":"Ju","year":"2013","journal-title":"Radiat Oncol"},{"key":"2023010721202101500_bib34","doi-asserted-by":"crossref","first-page":"185","DOI":"10.3389\/fonc.2016.00185","article-title":"Dose-escalated stereotactic body radiation therapy for prostate cancer: Quality-of-life comparison of two prospective trials","volume":"6","author":"Quon","year":"2016","journal-title":"Front Oncol"},{"key":"2023010721202101500_bib35","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/1471-2490-10-1","article-title":"Stereotactic body radiotherapy for organ-confined prostate cancer","volume":"10","author":"Katz","year":"2010","journal-title":"BMC Urol"},{"key":"2023010721202101500_bib36","doi-asserted-by":"crossref","first-page":"301","DOI":"10.3389\/fonc.2014.00301","article-title":"Quality of life and toxicity after SBRT for organ-confined prostate cancer, a 7-year study","volume":"4","author":"Katz","year":"2014","journal-title":"Front Oncol"},{"key":"2023010721202101500_bib37","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1186\/1756-8722-4-12","article-title":"Low incidence of new biochemical and clinical hypogonadism following hypofractionated stereotactic body radiation therapy (SBRT) monotherapy for low- to intermediate-risk prostate cancer","volume":"4","author":"Oermann","year":"2011","journal-title":"J Hematol Oncol"},{"key":"2023010721202101500_bib38","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1016\/j.ijrobp.2010.11.054","article-title":"Long-term outcomes from a prospective trial of stereotactic body radiotherapy for low-risk prostate cancer","volume":"82","author":"King","year":"2012","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"2023010721202101500_bib39","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1186\/1748-717X-9-52","article-title":"Patient-reported outcomes following stereotactic body radiation therapy for clinically localized prostate cancer","volume":"9","author":"Bhattasali","year":"2014","journal-title":"Radiat Oncol"},{"key":"2023010721202101500_bib40","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1016\/j.ejca.2016.02.014","article-title":"Stereotactic body radiation therapy for low and intermediate risk prostate cancer\u2014Results from a multi-institutional clinical trial","volume":"59","author":"Hannan","year":"2016","journal-title":"Eur J Cancer"},{"key":"2023010721202101500_bib41","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/j.radonc.2013.03.022","article-title":"Prostate stereotactic ablative body radiotherapy using a standard linear accelerator: Toxicity, biochemical, and pathological outcomes","volume":"107","author":"Loblaw","year":"2013","journal-title":"Radiother Oncol"},{"key":"2023010721202101500_bib42","doi-asserted-by":"crossref","first-page":"1795","DOI":"10.1007\/s00432-014-1732-1","article-title":"Stereotactic body radiotherapy with flattening filter-free beams for prostate cancer: assessment of patient-reported quality of life","volume":"140","author":"Scorsetti","year":"2014","journal-title":"J Cancer Res Clin Oncol"},{"key":"2023010721202101500_bib43","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1186\/s13014-015-0488-3","article-title":"Sexual, irritative, and voiding outcomes, following stereotactic body radiation therapy for prostate cancer","volume":"10","author":"Rana","year":"2015","journal-title":"Radiat Oncol"},{"key":"2023010721202101500_bib44","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1016\/j.ijrobp.2009.07.1748","article-title":"Sexual function after stereotactic body radiotherapy for prostate cancer: Results of a prospective clinical trial","volume":"78","author":"Wiegner","year":"2010","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"2023010721202101500_bib45","doi-asserted-by":"crossref","first-page":"279","DOI":"10.3389\/fonc.2014.00279","article-title":"A phase II trial of stereotactic ablative body radiotherapy for low-risk prostate cancer using a non-robotic linear accelerator and real-time target tracking: Report of toxicity, quality of life, and disease control outcomes with 5-year minimum follow-up","volume":"4","author":"Mantz","year":"2014","journal-title":"Front Oncol"},{"key":"2023010721202101500_bib46","doi-asserted-by":"crossref","first-page":"3681","DOI":"10.1002\/cncr.26699","article-title":"Hypofractionated stereotactic body radiotherapy in low-risk prostate adenocarcinoma: Preliminary results of a multi-institutional phase 1 feasibility trial","volume":"118","author":"McBride","year":"2012","journal-title":"Cancer"},{"key":"2023010721202101500_bib47","doi-asserted-by":"crossref","first-page":"1099","DOI":"10.1016\/j.ijrobp.2006.10.050","article-title":"Stereotactic hypofractionated accurate radiotherapy of the prostate (SHARP), 33.5 Gy in five fractions for localized disease: first clinical trial results","volume":"67","author":"Madsen","year":"2007","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"2023010721202101500_bib48","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1186\/s13014-016-0758-8","article-title":"Toxicity and quality of life report of a phase II study of stereotactic body radiotherapy (SBRT) for low and intermediate risk prostate cancer","volume":"12","author":"Boyer","year":"2017","journal-title":"Radiat Oncol"},{"key":"2023010721202101500_bib49","doi-asserted-by":"crossref","first-page":"321","DOI":"10.3389\/fonc.2014.00321","article-title":"Virtual HDR CyberKnife SBRT for localized prostatic carcinoma: 5-year disease-free survival and toxicity observations","volume":"4","author":"Fuller","year":"2014","journal-title":"Front Oncol"},{"key":"2023010721202101500_bib50","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1111\/bju.13962","article-title":"Erectile Function after Stereotactic Body Radiotherapy for Localized Prostate Cancer","volume":"121","author":"Dess","year":"2018","journal-title":"BJU Int"},{"key":"2023010721202101500_bib51","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1038\/ijir.2013.28","article-title":"Erectile dysfunction after radiotherapy for prostate cancer: a model assessing the conflicting literature on dose-volume effects","volume":"25","author":"Rivin del Campo","year":"2013","journal-title":"Int J Impot Res"},{"key":"2023010721202101500_bib52","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/j.ctro.2018.09.006","article-title":"Dose to penile bulb is not associated with erectile dysfunction 18\u202fmonths post radiotherapy: A secondary analysis of a randomized trial","volume":"13","author":"T\u00f8ndel","year":"2018","journal-title":"Clin Transl Radiat Oncol"},{"key":"2023010721202101500_bib53","doi-asserted-by":"crossref","first-page":"1695","DOI":"10.1016\/j.jsxm.2016.08.012","article-title":"Sexual function after hypofractionated versus conventionally fractionated radiotherapy for prostate cancer: Results From the randomized phase III HYPRO Trial","volume":"13","author":"Wortel","year":"2016","journal-title":"J Sex Med"},{"key":"2023010721202101500_bib54","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.1016\/S1470-2045(16)30102-4","article-title":"Conventional versus hypofractionated high-dose intensity-modulated radiotherapy for prostate cancer: 5-year outcomes of the randomised, non-inferiority, phase 3 CHHiP trial","volume":"17","author":"Dearnaley","year":"2016","journal-title":"Lancet Oncol"},{"key":"2023010721202101500_bib55","doi-asserted-by":"crossref","first-page":"1605","DOI":"10.1016\/S1470-2045(15)00280-6","article-title":"Hypofractionated radiotherapy versus conventionally fractionated radiotherapy for patients with intermediate-risk localised prostate cancer: 2-year patient-reported outcomes of the randomised, non-inferiority, phase 3 CHHiP trial","volume":"16","author":"Wilkins","year":"2015","journal-title":"Lancet Oncol"},{"key":"2023010721202101500_bib56","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.1016\/j.jsxm.2017.07.010","article-title":"The natural history of erectile dysfunction after prostatic radiotherapy: A systematic review and meta-analysis","volume":"14","author":"Gaither","year":"2017","journal-title":"J Sex Med"},{"key":"2023010721202101500_bib57","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/j.adro.2016.05.003","article-title":"Radiation-induced erectile dysfunction: Recent advances and future directions","volume":"1","author":"Mahmood","year":"2016","journal-title":"Adv Radiat Oncol"},{"key":"2023010721202101500_bib58","doi-asserted-by":"crossref","first-page":"e198","DOI":"10.1016\/S1470-2045(16)00063-2","article-title":"Vessel-sparing radiation and functional anatomy-based preservation for erectile function after prostate radiotherapy","volume":"17","author":"Lee","year":"2016","journal-title":"Lancet Oncol"},{"issue":"3 Suppl","key":"2023010721202101500_bib59","doi-asserted-by":"crossref","first-page":"S130","DOI":"10.1016\/j.ijrobp.2009.04.094","article-title":"Radiation dose-volume effects and the penile bulb","volume":"76","author":"Roach","year":"2010","journal-title":"Int J Radiat Oncol Biol Phys"}],"container-title":["The Journal of Sexual Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1743609519312305?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1743609519312305?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/academic.oup.com\/jsm\/article-pdf\/16\/9\/1409\/48477107\/jsm_16_9_1409.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jsm\/article-pdf\/16\/9\/1409\/48477107\/jsm_16_9_1409.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,1,7]],"date-time":"2023-01-07T21:21:40Z","timestamp":1673126500000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jsm\/article\/16\/9\/1409\/6966782"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,7,11]]},"references-count":59,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2019,7,11]]},"published-print":{"date-parts":[[2019,9,1]]}},"URL":"https:\/\/doi.org\/10.1016\/j.jsxm.2019.05.019","relation":{},"ISSN":["1743-6109","1743-6095"],"issn-type":[{"value":"1743-6109","type":"electronic"},{"value":"1743-6095","type":"print"}],"subject":[],"published-other":{"date-parts":[[2019,9]]},"published":{"date-parts":[[2019,7,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Sexual Function in Patients Treated With Stereotactic Radiotherapy For Prostate Cancer: A Systematic Review of the Current Evidence","name":"articletitle","label":"Article Title"},{"value":"The Journal of Sexual Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jsxm.2019.05.019","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 International Society for Sexual Medicine. Published by Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}